Spero Therapeutics (SPRO) Current Assets (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Current Assets came in at $57.6 million in Q1 2026, down 22.89% YoY from $74.7 million in Q1 2025, and down 14.38% on a QoQ basis from $67.3 million in Q4 2025.
Spero Therapeutics (SPRO) Current Assets (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Current Assets data on file, last reported at $57.6 million in Q1 2026.
- Quarterly Current Assets fell 22.89% year-over-year to $57.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.6 million (down 22.89% YoY) and the FY2025 annual result came in at $67.3 million, down 37.28% from the prior year.
- Current Assets slipped to $57.6 million in Q1 2026, from $67.3 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $140.2 million in Q1 2024 to a low of $52.0 million in Q2 2022.
- A 5-year average of $93.4 million and a median of $101.7 million in 2023 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets jumped 93.28% — and 2025, when it sank 60.25%.
- Tracing SPRO's Current Assets over 5 years: stood at $113.6 million in 2022, then gained by 15.53% to $131.2 million in 2023, then decreased by 18.24% to $107.3 million in 2024, then tumbled by 37.28% to $67.3 million in 2025, then fell by 14.38% to $57.6 million in 2026.
- The last three Current Assets figures came in at $57.6 million (Q1 2026), $67.3 million (Q4 2025), and $52.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 51.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.58 Mn |
| Mar 31, 2026 | 57.61 Mn |
| Dec 31, 2025 | 67.29 Mn |
| Sep 30, 2025 | 52.32 Mn |
| Jun 30, 2025 | 59.40 Mn |
| Mar 31, 2025 | 74.71 Mn |
| Dec 31, 2024 | 107.28 Mn |
| Sep 30, 2024 | 131.63 Mn |
| Jun 30, 2024 | 122.22 Mn |
| Mar 31, 2024 | 140.15 Mn |
| Dec 31, 2023 | 131.21 Mn |
| Sep 30, 2023 | 102.22 Mn |
| Jun 30, 2023 | 88.35 Mn |
| Mar 31, 2023 | 101.66 Mn |
| Dec 31, 2022 | 113.57 Mn |
| Sep 30, 2022 | 52.89 Mn |
| Jun 30, 2022 | 51.95 Mn |
| Mar 31, 2022 | 132.70 Mn |
| Dec 31, 2021 | 157.87 Mn |
| Sep 30, 2021 | 131.77 Mn |